726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)

Abstract

Study 309/KEYNOTE-775 (NCT03517449) is a phase III trial comparing efficacy and safety of lenvatinib (LEN) + pembrolizumab (pembro) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated, advanced endometrial cancer (EC). LEN + pembro significantly improved OS and PFS vs TPC in the ITT population (all comers) (HR [95% CI]: OS 0.62 [0.51−0.75]; PFS 0.56 [0.47−0.66]) and in pts with mismatch repair-proficient (pMMR) status (HR [95% CI]: OS 0.68 [0.56−0.84]; PFS 0.60 [0.50−0.72]).